Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study
Latest Information Update: 18 Mar 2024
At a glance
- Drugs Beclometasone/formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms TriNEXT
- Sponsors Chiesi SAS
Most Recent Events
- 12 Mar 2024 Status changed from not yet recruiting to recruiting.
- 20 Jul 2023 New trial record